Nevertheless, in CLL patients, the predominant resistance mechanism to the BTK inhibitor ibrutinib is mutations in the BTK gene [16,17,18], and similar resistance mechanisms are also observed with next-generation inhibitors such as acalabrutinib [19]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.